CP
CPRX

CenterBook Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

CenterBook Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-48,464
Closed -$1.13M – 676
2025
Q4 		$1.13M Buy
48,464
+36,556
+307% +$814K 0.06% 347
2025
Q3 		$235K Sell
11,908
-3,031
-20% -$62.3K 0.01% 536
2025
Q2 		$324K Buy
+14,939
New +$353K 0.02% 481
2023
Q4 		– Sell
-13,577
Closed -$159K – 408
2023
Q3 		$159K Buy
13,577
+2,259
+20% +$30.2K 0.02% 403
2023
Q2 		$152K Buy
+11,318
New +$163K 0.02% 397
2022
Q4 		– Sell
-26,231
Closed -$337K – 396
2022
Q3 		$337K Buy
+26,231
New +$311K 0.07% 325

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

CenterBook Partners's CPRX Position: Q1 2026 in Review

CenterBook Partners sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 48,464 shares — an estimated $1.13M sold.

CenterBook Partners first reported a position in CPRX in Q3 2022 and held it in 6 quarters. The position peaked at $1.13M in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • CenterBook Partners reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • CenterBook Partners sold 48,464 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.13M.
  • CenterBook Partners first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 6 quarters.
  • CenterBook Partners's Catalyst Pharmaceutical position peaked at $1.13M in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on CenterBook Partners's 13F filing for Q1 2026, filed 5 May 2026.